Promethera Biosciences treats first patients with Promethera HepaStem
Phase I/II study designed to evaluate the ability of liver progenitor cells to restore a missing enzyme function in liver-based metabolic diseases
16-May-2012 -
Promethera Biosciences, a Belgian biotechnology company developing Promethera (R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced it has treated its first two patients with its treatment based ...
metabolic diseases
stem cells